ArticleCardiovascular drugs and therapy2023
Empagliflozin Ameliorates Ouabain-Induced Na
Article in Cardiovascular drugs and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- SGLT2 inhibitors: how do they affect the cardiac cells.Molecular and cellular biochemistry · 2025Review
- Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.Basic research in cardiology · 2024Article
- Winding Down the Storm: Could Empagliflozin's Ion-Dependent Mechanisms Tackle the Ventricular Arrhythmia Burden in Chronic Chagas Cardiomyopathy?Cardiovascular drugs and therapy · 2024Article
- Hypoxic Stress-Dependent Regulation of Na,K-ATPase in Ischemic Heart Disease.International journal of molecular sciences · 2023Review
- Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells.Frontiers in physiology · 2023Article
- A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena.World journal of diabetes · 2022Review
- The Remaining Conundrum of the Role of the NaReviews in cardiovascular medicine · 2022Review
- Direct cardiac effects of SGLT2 inhibitors.Cardiovascular diabetology · 2022Review
- SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?Cardiology in reviewReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
purposeSodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of glucose-lowering agents that have improved clinical outcomes in patients with heart failure; however, their therapeutic mechanisms remain elusive. Although contradictory results have been reported, it has been proposed that improving Na
methodsIsolated ventricular myocytes of mice were incubated with ouabain to establish a cellular model of Na
resultsIn the absence of ouabain, 1 μmol/L empagliflozin had a negligible impact on Na
conclusionEmpagliflozin ameliorates ouabain-induced Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.